Cargando…
Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
[Image: see text] Increasingly resistant Enterobacteriaceae have emerged as a health threat in both hospital and community settings. Infections of the urinary tract, once often treated with oral agents in the community, are requiring increased hospitalization and use of intravenously administered ag...
Autores principales: | O’Donnell, John, Tanudra, Angela, Chen, April, Hines, Daniel, Tommasi, Ruben, Mueller, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297445/ https://www.ncbi.nlm.nih.gov/pubmed/32379415 http://dx.doi.org/10.1021/acsinfecdis.0c00019 |
Ejemplares similares
-
Discovery of an
Orally Available Diazabicyclooctane
Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases
por: Durand-Réville, Thomas F., et al.
Publicado: (2020) -
Interactions of the Diazabicyclooctane Serine β-Lactamase
Inhibitor ETX1317 with Target Enzymes
por: Shapiro, Adam B., et al.
Publicado: (2020) -
Using the Meade ETX: 100 objects you can really see with the mighty etx
por: Weasner, Mike
Publicado: (2002) -
ETX1 is over-expressed in the glaucomatous trabecular meshwork
por: Iragavarapu, Saradha, et al.
Publicado: (2009) -
The Novel β-Lactamase Inhibitor, ETX-2514, in Combination with Sulbactam Effectively Inhibits Acinetobacter baumannii
por: Barnes, Melissa D, et al.
Publicado: (2017)